Quality of Life Measurement in Treatment Naïve Patients With Hepatitis C Virus (HCV) Genotype 1 (GT1) Suffering From Fatigue and Receiving Ombitasvir, Paritaprevir, and Ritonavir and Dasabuvir (Viekirax®/Exviera®)

CompletedOBSERVATIONAL

Enrollment

Participants

Timeline

Start Date

March 1, 2017

Primary Completion Date

April 25, 2018

Study Completion Date

April 25, 2018

Conditions

Chronic Hepatitis C Virus (HCV)

Trial Locations (5)

Inselspital, Universitaetsklin, Bern

Fondazione Epatocentro Ticino, Lugano

Universitaetsspital Zuerich, Zurich

Kantonsspital St. Gallen, Sankt Gallen

Hopital Neuchatelois, Neuchâtel